Niederer Kraft Frey (NKF) advised AB2 Bio, a Swiss biotechnology company, on Swiss law matters in connection with the entry into an option and licensing agreement with Japanese pharmaceutical company Nippon Shinyaku. The context Headquartered
Niederer Kraft Frey (NKF) advised AB2 Bio, a Swiss biotechnology company, on Swiss law matters in connection with the entry into an option and licensing agreement with Japanese pharmaceutical company Nippon Shinyaku. The context Headquartered